Savara ApS

https://www.savarapharma.com

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3-stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. *

	Start	2019-12-30 existent
	Group	Savara (Group)
	Industry	respiratory drug delivery technology

	Region	Hørsholm
	Country	Denmark
	Street	17 Slotsmarken 1 th.
	City	2970 Hørsholm
	Tel	+45-7930-1414
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Savara Inc.. (12/20/19). "Press Release: Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million". Austin, TX.

		Record changed: 2024-02-12

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Savara (Group)

[1] Savara Inc.. (12/20/19). "Press Release: Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million". Austin, TX....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)